In fact, an initial study on the use of the anti-BCMA 1-E6 affibody—developed in the present work—as the tumour antigen-binding unit in a BCMA × CD16a dual engager for NK cell-mediated killing of MM.1s cells in vitro, has yielded encouraging results [22]. This evidence concerns the gene FCGR3A and neoplasm.